pharmaceuticals

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) reported first-quarter earnings of 16 cents per share, compared to a loss of 7 cents a year ago. This beat the consensus of 10 cents. The biopharma company reported fourth-quarter sales of $62.47 million, up 24% year over year, almost in line with the...

As the drug industry is in the middle of a growing policy maelstrom in Washington, D.C., investors are closely watching pharmaceutical ETFs to measure market sentiment and ride out the emerging volatility. With President Donald Trump’s administration rehashing contentious ideas on drug...

Cencora, Inc (NYSE:COR) on Wednesday reported second-quarter 2025 sales increased 10.3% to $75.5 billion, missing the consensus of $75.68 billion, primarily due to an 11.4% increase in revenue within the U.S. Healthcare Solutions segment. U.S. Healthcare Solutions revenue was $68.3...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shares are sinking after the company released its first-quarter results after Tuesday's closing bell. Here's a look at the details from the report.  The Details: Sarepta Therapeutics reported quarterly losses of $3.42 per share, which missed the analyst...

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reported first-quarter financial results after the market close on Monday. Here’s a look at the key highlights from the period. Q1 Revenue: $2.77 billion versus estimates of $2.85 billion Q1 EPS: $4.06, versus estimates of $4.32 Total revenue grew...

Axsome Therapeutics Inc (NASDAQ:AXSM) on Monday reported first-quarter 2025 revenues of $121.5 million, up from $75 million a year ago, beating the consensus of $119.87 million. Auvelity (oral antidepressant) net product sales for the quarter were $96.2 million, up 80% year over year....

Amneal Pharmaceuticals Inc. (NASDAQ:AMRX) reported first-quarter 2025 adjusted EPS of 21 cents, up from 14 cents a year ago, and beating the consensus of 15 cents. The company reported sales of $695.42 million, up 5% year-over-year, missing the consensus of $715.49 million....

Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the first quarter of 2025 adjusted earnings per share was $3.02. That’s down from $3.67 a year ago, beating the analyst consensus of $2.52. The company reported sales of $2.43 billion, up 6% year over year on a reported basis, 8% on constant...

Eli Lilly And Co (NYSE:LLY) will be reporting its first-quarter earnings on Thursday. Wall Street expects $3.05 in EPS and $12.67 billion in revenues as the company reports before market hours. The stock is up 14.35% over the past year, 14.79% YTD. Let’s examine the charts for Eli Lilly stock...

Ionis Pharmaceuticals Inc (NASDAQ:IONS) reported a first-quarter EPS loss of 93 cents on Wednesday, down from a loss of 98 cents, beating the consensus of a $1.12 loss. Revenue increased 10% in the first quarter of 2025 to $132 million, beating the consensus of $125.32 million, driven by...

On Friday, AbbVie Inc (NYSE:ABBV) reported an adjusted EPS of $2.46, up 6.5% year over year and beating the consensus of $2.38. The pharmaceutical giant reported sales of $13.34 billion, up 8.4% on a reported basis (+9.8% on an operational basis), beating the consensus of $12.92 billion. It...

Merck & Co. Inc‘s (NYSE:MRK) M&A efforts will continue. That’s according to a Goldman Sachs analyst report, which details the company’s growth strategy. Analyst Asad Haider explained in a Friday note that Merck acknowledges that deal-making is getting more complex. However...

Merck & Co Inc (NYSE:MRK) will be reporting its first-quarter earnings on Thursday before the market opens. Wall Street expects earnings per share of $2.14 and revenue of $15.33 billion. The stock is down a painful 38.04% over the past year and has dropped 20.73% year-to-date. Even in the past...

Cantor Fitzgerald initiated coverage on Eli Lilly And Co (NYSE:LLY) on Monday, citing orforglipron data, which strengthens the case for obesity dominance. Last week, the U.S. drug giant reported topline Phase 3 results from the ACHIEVE-1 trial of orforglipron compared to placebo in adults with type...

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) is entering earnings week with some serious anticipation — and a bit of heartburn. The stock had a solid run in 2025, up nearly 20% year-to-date and 21% over the past 12 months. But with a 3.5% pullback in the past month, all eyes are now on its first-...